Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02513550 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,257
- Enrollment target
NCT02513550: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT02513550 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,257 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02513550, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,257 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
Primary Outcome
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criter
Interventions
- DRUG Placebo
- DRUG Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,257 participants |
| Start Date | 2015-08 |
| Est. Completion | 2017-08-03 |
| Phase | Phase 3 |
What the finished NCT02513550 record still lists
NCT02513550 is an interventional study that assigns participants to a tested intervention. Its 1,257 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02513550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02513550 about?
NCT02513550 is a clinical study titled "A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis". The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.
What is the current status of trial NCT02513550?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,257 participants. The study started on 2015-08. Estimated completion is 2017-08-03.
What interventions are being tested in trial NCT02513550?
The interventions under investigation include: Placebo (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT02513550?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02513550's enrollment target sits among peer trials
1,257 205th of 2000 higher than 1,796 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia